CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
Former cancer patient, Judy Needham is the Chair of the Canadian Cancer Trials Group (CCTG) Patient Representatives Committee (formerly Lay Committee). She talks about the role of the patient voice in the development of clinical trials. Before partnering with CCTG, Judy was a board member of the former BC chapter of the Canadian Breast Cancer Foundation, championing the first Breast Cancer Navigation Map, a patient tool aimed at simplifying the breast cancer journey. Since 2012, Ms.
Dr Daniel Renouf is the pancreatic cancer disease site chair and in this interview he discusses the PA7 trail which explores whether adding immunotherapy to chemotherapy can improve the efficacy or the positive effects of treatment for patients
600 PATIENTS RANDOMIZED!!!
Congratulations to Dr. Willibald Schroeder and the team at GYNAEKOLOGICUM Bremen, Germany for enrolling the 600th patient to the SHAPE study! On behalf of the SHAPE trial committee, we would like to thank you for your tremendous and unwavering support of our trial. The countdown is on....let's see the SHAPE trial reach its accrual goal by the end of 2019!
HN10, A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma, is centrally activated.
Seymour L, Le Teuff G, Brambilla E, Shepherd FA, Soria JC, Kratzke R, Graziano S, Douillard JY, Rosell R, Reiman A, Lacas B, Lueza B, viel-Ronen S, McLeer A, Le Chevalier T, Pirker R, Filipits M, Dunant A, Pignon JP, Tsao MS.
The CCTG Annual Spring Meeting of Participants is almost here, if you are planning meetings and/or attending the Spring Meeting please read the information below:
The Supportive Care Committee and Lung Disease Site are actively seeking a CRA representative volunteer from our Canadian centres.
